Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2013, Article ID 165789, 8 pages
Clinical Study

Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation—The POWER Survey

1Department of Public Health, Ghent University Hospital, DePintelaan 185, 9000 Ghent, Belgium
2Department of Family Medicine and Cardiology, Lawson Health Research Institute, 801 Commissioners Road East, University of Western Ontario, ON, Canada N6C 5J1
3Preventive Cardiology Clinic, Department of Internal Medicine, Medical University of Sofia, Sofia 1431, Bulgaria
4Rashid Hospital, P.O. Box 4545, Oud Metha Road, Dubai, UAE
5Department of Cardiology, Medical University of Gdañsk, M. Skłodowskiej-Curie 3a Street, 80-210 Gdañsk, Poland
6Clinical Pharmacology Service, INSERM Unit 1048, Faculty of Medicine, University Hospital Toulouse, 1073 Toulouse, France

Received 19 March 2013; Revised 21 May 2013; Accepted 4 June 2013

Academic Editor: Kazuomi Kario

Copyright © 2013 Guy De Backer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. High blood pressure is a substantial risk factor for cardiovascular disease. Design & Methods. The Physicians' Observational Work on patient Education according to their vascular Risk (POWER) survey was an open-label investigation of eprosartan-based therapy (EBT) for control of high blood pressure in primary care centers in 16 countries. A prespecified element of this research was appraisal of the impact of EBT on estimated 10-year risk of a fatal cardiovascular event as determined by the Systematic Coronary Risk Evaluation (SCORE) model. Results. SCORE estimates of CVD risk were obtained at baseline from 12,718 patients in 15 countries (6504 men) and from 9577 patients at 6 months. During EBT mean (±SD) systolic/diastolic blood pressures declined from 160.2 ± 13.7/94.1 ± 9.1 mmHg to 134.5 ± 11.2/81.4 ± 7.4 mmHg. This was accompanied by a 38% reduction in mean SCORE-estimated CVD risk and an improvement in SCORE risk classification of one category or more in 3506 patients (36.6%). Conclusion. Experience in POWER affirms that (a) effective pharmacological control of blood pressure is feasible in the primary care setting and is accompanied by a reduction in total CVD risk and (b) the SCORE instrument is effective in this setting for the monitoring of total CVD risk.